Loading…
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $12M | $48M | $32M | $-18M | 37.8% | 14.1% | -329.4% |
| 2024 | $10M | $-5M | $-14M | $-14M | -22.3% | 114.8% | -66.2% |
| 2023 | $5M | $-39M | $-41M | $-18M | -46.0% | -21.1% | 138.7% |
| 2022 | $6M | $-17M | $-17M | $-28M | -13.8% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 6.03 | 4.76 | 10.22 | 11.66 |
| Operating Revenue | - | 6.03 | 4.76 | 10.22 | 11.66 |
| Operating Expense | - | 23.44 | 28.22 | 50.20 | 0.28 |
| Research And Development | - | 0.15 | 0.14 | 2.88 | 1.71 |
| Selling General And Administration | - | 23.19 | 25.61 | 34.48 | 36.09 |
| Total Expenses | - | 23.44 | 28.22 | 50.20 | 0.28 |
| Operating Income | - | -17.41 | -23.46 | -39.98 | 11.38 |
| Total Operating Income As Reported | - | -17.41 | -41.85 | -39.98 | 11.38 |
| EBITDA | - | -17.02 | -39.36 | -5.42 | 47.82 |
| Normalized EBITDA | - | -17.27 | -22.49 | -39.46 | 19.37 |
| EBIT | - | -17.12 | -40.26 | -5.64 | 44.85 |
| Interest Expense | - | 0 | 0.57 | 13.84 | 13.03 |
| Net Interest Income | - | 0 | -0.57 | -13.84 | -13.03 |
| Other Non Operating Income Expenses | - | 0.04 | 0.08 | 0.30 | 5.01 |
| Other Income Expense | - | 0.30 | -16.80 | 34.34 | 33.46 |
| Interest Expense Non Operating | - | 0 | 0.57 | 13.84 | 13.03 |
| Net Non Operating Interest Income Expense | - | 0 | -0.57 | -13.84 | -13.03 |
| Pretax Income | - | -17.12 | -40.83 | -19.48 | 31.82 |
| Tax Provision | - | -0.02 | 0 | -5.66 | 0.10 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 9.89 | 0 |
| Net Income Continuous Operations | - | -17.10 | -40.83 | -13.82 | 31.71 |
| Net Income From Continuing And Discontinued Operation | - | -17.10 | -40.83 | -13.82 | 31.71 |
| Net Income From Continuing Operation Net Minority Interest | - | -17.10 | -40.83 | -13.82 | 31.71 |
| Net Income | - | -17.10 | -40.83 | -13.82 | 31.71 |
| Net Income Common Stockholders | - | -22.58 | -46.30 | -19.29 | 18.52 |
| Net Income Including Noncontrolling Interests | - | -17.10 | -40.83 | -13.82 | 31.71 |
| Normalized Income | - | -17.36 | -23.96 | -37.97 | 3.26 |
| Diluted NI Availto Com Stockholders | - | -22.58 | -46.30 | -19.29 | 26.18 |
| Basic Average Shares | - | 11.41 | 11.47 | 11.70 | 12.08 |
| Diluted Average Shares | - | 11.41 | 11.47 | 11.70 | 17.98 |
| Reconciled Depreciation | - | 0.10 | 0.90 | 0.22 | 2.97 |
| Total Unusual Items | - | 0.26 | -16.87 | 34.04 | 28.45 |
| Total Unusual Items Excluding Goodwill | - | 0.26 | -16.87 | 34.04 | 28.45 |
| Preferred Stock Dividends | - | 5.47 | 5.47 | 5.47 | 5.53 |
| Special Income Charges | - | 0 | -18.39 | 19.32 | 21.22 |
| Other Special Charges | 0.30 | - | 4.13 | - | - |
| Write Off | - | 0 | 14.25 | 0 | - |
| Impairment Of Capital Assets | - | 0 | 15.83 | - | - |
| Restructuring And Mergern Acquisition | - | 0 | 0 | -19.32 | -21.22 |
| Gain On Sale Of Security | - | 0.26 | 1.51 | 14.72 | 7.22 |
| Depreciation Amortization Depletion Income Statement | - | 0.10 | 0.90 | 0.21 | 2.96 |
| Depreciation And Amortization In Income Statement | - | 0.10 | 0.90 | 0.21 | 2.96 |
| General And Administrative Expense | - | 23.19 | 25.61 | 34.48 | 36.09 |
| Other Gand A | - | 23.19 | 25.61 | 34.48 | 36.09 |
| Other Operating Expenses | - | - | - | -18.27 | -40.49 |
| Provision For Doubtful Accounts | - | - | 1.58 | 30.90 | 0 |
| Otherunder Preferred Stock Dividend | 3.45 | 0 | - | - | 7.67 |
| Average Dilution Earnings | 0.18 | 0 | - | - | 7.67 |
| Amortization | - | 0.10 | 0.90 | 0.21 | 2.96 |
| Amortization Of Intangibles Income Statement | - | 0.10 | 0.90 | 0.21 | 2.96 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| XOMA Royalty Corporationthis co. | XOMA | $532M | 16.77 | 6.34 | 37.8% | 12.14 |
| Cerus Corporation | CERS | $559M | - | 8.70 | -24.3% | - |
| NeuroPace, Inc. | NPCE | $556M | -25.92 | 29.24 | -112.8% | -50.21 |
| Fulgent Genetics, Inc. | FLGT | $554M | -9.15 | 0.50 | -5.4% | -11.16 |
| Tectonic Therapeutic, Inc. | TECX | $550M | -7.41 |
| - |
| - |
| - |
| - |
| - |
| - |
| 2.19 |
| -29.5% |
| -4.16 |
| Strata Critical Medical, Inc. | SRTA | $542M | 13.10 | 1.94 | 14.8% | -36.28 |
| 4D Molecular Therapeutics, Inc. | FDMT | $523M | -3.73 | 1.03 | -27.7% | -3.19 |
| Aquestive Therapeutics, Inc. | AQST | $519M | -6.20 | -15.43 | 248.9% | -6.66 |
| Pacific Biosciences of California, Inc. | PACB | $506M | -0.93 | 94.65 | -10214.5% | -7.50 |
| Peer Median | - | -6.20 | 2.06 | -26.0% | -7.50 | |